Since the Look Ahead was published, substantial progress has been made in diabetes care with advent of drugs such as GLP-1 agonists, SGLT-2 inhibitors that are either weight loss enhancing or weight neutral while having cardiovascular benefits at the same time. This evidence concerns the gene SLC5A2 and diabetes mellitus.